RuDo Logo
Talk to an adviser

HDFC Pharma and Healthcare Fund

Pharma and Healthcare · Direct plan · Growth

₹23.52

+₹0.10 (+0.44%) today

NAV on 19 Nov 2026Near its 52-week high

This fund +31.59%BSE Healthcare +18.52%past 5 days

Returns

Up to a year

PeriodThis fundBSE HealthcareRank
1 month+12.22%+10.80%6/19
3 months+6.35%+4.61%3/18
6 months+17.38%+11.27%2/18
This year+32.83%+20.82%2/18
1 year+31.59%+18.52%2/17

Longer term

This fundBSE Healthcare
TotalA yearA yearRank
2 years+45.86%+20.8%+11.7%–
3 years+123.0%+30.6%+22.4%1/12
5 years––+15.8%–
7 years––+21.9%–
10 years––+13.3%–
Since inception+136.0%+31.6%+22.0%–

₹1 lakh invested 3 years ago is ₹2.23 lakh today.

From the plan's own NAV, to 19 Nov 2026. Rank 1 is best. Past returns are no guide to the future.

RiskWorst fall -14.9% · volatility 16.1% a year

Volatility, 3 years

16.1%

BSE Healthcare 16.1%

Worst fall

-14.9%

Feb 2025, back by Jul 2025

Worst calendar year

+2.4%

2025

Up months

72%

last 3 years

Against other pharma and healthcare funds, last 3 years (worst fall: 5 years)

Volatility

= 16.1%

In line with peers · average 16.0%

8 of 13

Sharpe ratio

✓ 1.53

More return for the risk · average 0.99

1 of 12

Yearly cost

= 1.04%

About average · average 1.10%

9 of 18

More measures ›

Sharpe ratio, 3 years

1.53

Return above the CRISIL Overnight Index per unit of volatility

Sortino ratio, 3 years

3.01

The same, counting only falls

Alpha vs BSE Healthcare

+9.11%

Yearly return beyond what its beta explains

Beta vs BSE Healthcare

1.00

Moves this much when the index moves 1%

Share of the index's rises

113%

In months the index rose

Share of the index's falls

80%

In months the index fell; lower is better

Over the last 3 years, from the fund's NAVs against the BSE Healthcare.

Where it ranksAgainst 19 pharma and healthcare funds

Category rank, year by year

In the top half of pharma and healthcare funds in 3 of 3 calendar years.

Top quarter in 3, bottom quarter in 0.

2/18

Rank in 2026 YTD

'17

N/A

'18

N/A

'19

N/A

'20

N/A

'21

N/A

'22

N/A

'23

N/A

'24

Q1

'25

Q1

'26

Q1

Each year ranks the pharma and healthcare funds by that year's return from their own Direct Growth NAV; Q1 is the top quarter. 2026 is year to date. The peer group is today's funds, so funds that closed or merged in earlier years are not counted. Past performance does not indicate future returns.

Where it ranks

among 19 pharma and healthcare funds, Direct plans

1 year

2 of 17

Top quarter

3 years

1 of 12

Top quarter

Lowest cost

9 of 18

Second quarter

Best over 3 years3 yearsCost
1HDFC Pharma and Healthcare Fund this fund+123.0%1.04%
2SBI Healthcare Opportunities Fund+94.4%1.00%
3Mirae Asset Healthcare Fund+90.9%0.61%
4UTI Healthcare Fund+87.3%1.34%
5LIC MF Healthcare Fund+80.9%1.38%

Every fund in the category computed from its own NAV the same way, to 20 Nov 2026. All Pharma and Healthcare funds ›

What stands out

What it holds

40 holdings · as of Aug 2026

  1. 1Divi'S Laboratories Ltd9.54%
  2. 2Sun Pharmaceutical Industries Ltd8.94%
  3. 3Torrent Pharmaceuticals Ltd4.08%
  4. 4Max Healthcare Institute Ltd4.06%
  5. 5Lupin Ltd4.04%
  6. 6Cipla Ltd3.94%
  7. 7Aster Dm Healthcare Ltd3.84%
  8. 8Neuland Laboratories Ltd3.70%
  9. 9Anthem Biosciences Ltd3.48%
  10. 10AMI Organics Ltd3.24%
Top 10: 48.9% of the fund
P/E 65.0 · Turnover 36% a yearCheck overlap with another fund ›

SIP returns of pharma and healthcare funds · All pharma and healthcare funds · Fund screener

About HDFC Pharma and Healthcare Fund Growth Option Direct Plan

HDFC Pharma and Healthcare Fund Growth Option Direct Plan is a Sector Specific - Pharma equity fund from HDFC Asset Management Company Limited, launched on 28 Sep 2023. Its benchmark is the BSE Healthcare Index. The expense ratio is 1.04% a year. It manages ₹3,666 crore. The NAV was ₹23.52 on 19 Nov 2026.

Questions about HDFC Pharma and Healthcare Fund

What is the NAV of HDFC Pharma and Healthcare Fund Direct Growth?

The NAV of HDFC Pharma and Healthcare Fund Direct Growth was ₹23.52 on 19 Nov 2026. Mutual fund NAVs are published once a day, after markets close.

What are the returns of HDFC Pharma and Healthcare Fund Direct Growth?

HDFC Pharma and Healthcare Fund Direct Growth returned 31.6% over 1 year and 30.6% a year over 3 years, to 19 Nov 2026, worked out from its own daily NAV. It returned more than the BSE Healthcare Index in 3 of 4 calendar years since 2023.

What is the expense ratio of HDFC Pharma and Healthcare Fund Direct Growth?

1.04% a year. It is taken from the fund's assets every day, so the NAV and every return shown are already after this cost.

Can NRIs in the UAE invest in HDFC Pharma and Healthcare Fund?

NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. HDFC Mutual Fund accepts investors living in the US only on conditions and does not accept investors living in Canada, per its own documents checked on 15 Nov 2026. Rules change, so confirm with the fund house.

How are HDFC Pharma and Healthcare Fund gains taxed for NRIs?

India taxes gains on equity funds at 20% on units held 12 months or less, and at 12.5% on gains above ₹1.25 lakh a year on units held longer, plus cess and any surcharge. For NRIs the tax is deducted when units are redeemed. The UAE has no personal income tax, and the India UAE tax treaty may apply, so confirm your position with a tax adviser.

Rolling returns shows every period, not just the latest.

Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.

Investing from the UAE. NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. Some fund houses restrict residents of the US and Canada. India taxes equity fund gains at 20% on units held 12 months or less and 12.5% above ₹1.25 lakh a year after that, plus cess and any surcharge, deducted when an NRI redeems. The UAE has no personal income tax and the India UAE treaty may apply, so confirm your position with a tax adviser.

Data from RuDo Wealth fund analytics, NAV as of 19 Nov 2026; benchmark as named by HDFC Asset Management Company Limited. India: RuDo Wealth Investment Advisory, SEBI Registered Investment Adviser, registration INA000019503. UAE: RuDo Digital Wealth, FSRA Financial Services Permission 220155, Category 3C (Retail), ADGM. General information, not a recommendation to buy or sell this fund. Past performance does not indicate future returns.